PharVision Advisers’s Sweetgreen SG Stock Holding History

PharVision Advisers’s Portfolio SG Stock Details SG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,827	Closed	-$61.4K	–	124
2026 Q1	$61.4K	Buy	+11,827	New	+$71.9K	0.62%	80

Other funds holding SG

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WCM

Woodson Capital Management Greenwich, Connecticut $597M AUM 48.9% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

PharVision Advisers's SG Position: Q2 2026 in Review

PharVision Advisers sold out of Sweetgreen (SG) in Q2 2026, closing a stake of 11,827 shares — an estimated $61.4K sold.

PharVision Advisers first reported a position in SG in Q1 2026 and held it in 1 quarter. The position peaked at $61.4K in Q1 2026. 236 funds tracked by Wall St. Rank hold SG as of Q2 2026.

PharVision Advisers reported no remaining Sweetgreen position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 11,827 Sweetgreen shares in Q2 2026, an estimated $61.4K.
PharVision Advisers first reported a position in Sweetgreen in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Sweetgreen position peaked at $61.4K in Q1 2026.
236 funds tracked by Wall St. Rank held Sweetgreen as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.